Therapeutical Implications

This study was a 10-week, prospective, multicentre, unmasked and uncontrolled (i.e., single group), 2-stage field trial to determine the efficacy of an extensively hydrolysed protein diet in reducing the clinical signs of CE in dogs. A research protocol was prepared before the study commenced, but this protocol was not pre-registered. The individual dog was the experimental unit within the trial.

CONFLICT OF INTEREST STATEMENT The authors declare that there is no conflict of interest. Supporting Information Filename Description bjh19561-sup-0001-FigureS1.docxWord 2007 document , 404.3 KB Figure S1. REFERENCES 1, , , , , , et al. Outcome of children with sickle cell disease admitted to intensive care – a single institution experience. Br J Haematol. 2010; 150: 614–617. 2, , , , , , et al. Outcomes of adult patients with sickle cell disease admitted to the ICU: a case series. Crit Care Med.

• , , , et al. Adults with haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean factor IX activity and durable haemostatic protection after 24 months’ follow-up . 16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023, 7–10 February 2023 , Manchester (PO156). • , , , , .